Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 7/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142203 | 0.86 | ALDH1A1 (0.48) | TSHRLMNAMAPTCYP1A2TP53 | |
| SCHEMBL1845428 | 0.83 | USP2 (0.44) | TSHRLMNAHTTMAPTCYP1A2 | |
| SCHEMBL8898023 | 0.83 | HTT (0.64) | TSHRLMNAHTTMAPTALDH1A1 | |
| SCHEMBL1921107 | 0.82 | ALDH1A1 (0.39) | TSHRLMNAHTTMAPTCYP1A2 | |
| SCHEMBL1846180 | 0.81 | ALDH1A1 (0.57) | TSHRCYP1A2ALDH1A1USP2POLB | |
| SCHEMBL1921365 | 0.81 | ALDH1A1 (0.40) | TSHRLMNAHTTMAPTCYP1A2 | |
| SCHEMBL1849473 | 0.81 | ALDH1A1 (0.48) | TSHRLMNACYP1A2ALDH1A1HPGD | |
| SCHEMBL1923248 | 0.80 | ALDH1A1 (0.47) | TSHRHSP90AB1HTTMAPTCYP1A2 | |
| Maleic Acid SCHEMBL29413890 | 0.75 | SMN1; SMN2 (0.42) | TSHRLMNAHTTMAPTPTPN11 | |
| SCHEMBL9685234 | 0.74 | HTT (0.62) | TSHRLMNAHTTMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302000-A1 | COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS | Progenicyte Therapeutics, Inc. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20210046079-A1 | COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2021-02-18 | — | — | US | disclosed |
| EP-1890673-A1 | USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES | DSMIP Assets B.V. (NL) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006133876-A1 | USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES | DSM IP ASSETS B.V. (NL) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046079-A1 | COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS | PSEN1, PSEN2, NES | TSHR 3594/4885LMNA 3338/4885HSP90AB1 1415/4885 |
| US-20230302000-A1 | COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS | NES, PSEN1, PSEN2 | TSHR 3492/4885LMNA 2159/4885HSP90AB1 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.